Etomidate hydrochlorideCAS# 53188-20-8 |
- Etifoxine
Catalog No.:BCC1560
CAS No.:21715-46-8
- Etifoxine hydrochloride
Catalog No.:BCC1561
CAS No.:56776-32-0
- Acamprosate calcium
Catalog No.:BCC1327
CAS No.:77337-73-6
- Flumazenil
Catalog No.:BCC1259
CAS No.:78755-81-4
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 53188-20-8 | SDF | Download SDF |
| PubChem ID | 198290 | Appearance | Powder |
| Formula | C14H17ClN2O2 | M.Wt | 280.75 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : ≥ 100 mg/mL (356.19 mM) H2O : ≥ 50 mg/mL (178.09 mM) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | ethyl 3-[(1R)-1-phenylethyl]imidazole-4-carboxylate;hydrochloride | ||
| SMILES | CCOC(=O)C1=CN=CN1C(C)C2=CC=CC=C2.Cl | ||
| Standard InChIKey | NCDXBSVHIGDPOE-RFVHGSKJSA-N | ||
| Standard InChI | InChI=1S/C14H16N2O2.ClH/c1-3-18-14(17)13-9-15-10-16(13)11(2)12-7-5-4-6-8-12;/h4-11H,3H2,1-2H3;1H/t11-;/m1./s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Etomidate hydrochloride Dilution Calculator
Etomidate hydrochloride Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 3.5619 mL | 17.8094 mL | 35.6189 mL | 71.2378 mL | 89.0472 mL |
| 5 mM | 0.7124 mL | 3.5619 mL | 7.1238 mL | 14.2476 mL | 17.8094 mL |
| 10 mM | 0.3562 mL | 1.7809 mL | 3.5619 mL | 7.1238 mL | 8.9047 mL |
| 50 mM | 0.0712 mL | 0.3562 mL | 0.7124 mL | 1.4248 mL | 1.7809 mL |
| 100 mM | 0.0356 mL | 0.1781 mL | 0.3562 mL | 0.7124 mL | 0.8905 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Etomidate is a GABAA receptors agonist, which is a short acting intravenous anaesthetic agent used for the induction of general anaesthesia.
- Fagomine
Catalog No.:BCC1569
CAS No.:53185-12-9
- 6-Aminoindole
Catalog No.:BCC8763
CAS No.:5318-27-4
- Pirfenidone
Catalog No.:BCC5086
CAS No.:53179-13-8
- Acemetacin
Catalog No.:BCC4424
CAS No.:53164-05-9
- Delphinidin-3-sambubioside chloride
Catalog No.:BCN3148
CAS No.:53158-73-9
- Euscaphic acid
Catalog No.:BCN5702
CAS No.:53155-25-2
- Buprenorphine hydrochloride
Catalog No.:BCC5215
CAS No.:53152-21-9
- Rapamycin (Sirolimus)
Catalog No.:BCC3592
CAS No.:53123-88-9
- Boc-Pyr-OH
Catalog No.:BCC3329
CAS No.:53100-44-0
- 4',7-Isoflavandiol
Catalog No.:BCN2855
CAS No.:531-95-3
- Coumarin-3-Carboxylic Acid
Catalog No.:BCC9220
CAS No.:531-81-7
- Esculin
Catalog No.:BCN5904
CAS No.:531-75-9
- Methyocarbamol
Catalog No.:BCC3813
CAS No.:532-03-6
- Anethole trithione
Catalog No.:BCN8510
CAS No.:532-11-6
- Tropinone
Catalog No.:BCN1935
CAS No.:532-24-1
- Euparin
Catalog No.:BCN7191
CAS No.:532-48-9
- ar-Turmerone
Catalog No.:BCN7516
CAS No.:532-65-0
- Coixol
Catalog No.:BCN5703
CAS No.:532-91-2
- 2''-O-Galloylhyperin
Catalog No.:BCN1218
CAS No.:53209-27-1
- H-Sar-NH2.HCl
Catalog No.:BCC3333
CAS No.:5325-64-4
- Boc-Tyr(Me)-OH
Catalog No.:BCC3268
CAS No.:53267-93-9
- [Ala11,D-Leu15]-Orexin B
Catalog No.:BCC5877
CAS No.:532932-99-3
- CV 1808
Catalog No.:BCC7163
CAS No.:53296-10-9
- Fmoc-Cys(Bzl)-OH
Catalog No.:BCC3475
CAS No.:53298-33-2
Intraoperative target-controlled infusion anesthesia application using remifentanil hydrochloride with etomidate in patients with severe burn as monitored using Narcotrend.[Pubmed:24931823]
Burns. 2015 Feb;41(1):100-5.
OBJECTIVE: This study aims to evaluate the feasibility of intraoperative composite target-controlled infusion (TCI) anesthesia application using remifentanil hydrochloride with etomidate in patients with severe burns, as monitored by Narcotrend. METHODS: A total of 40 patients with severe burns with eschar excisions and skin grafts were randomly and equally grouped into the etomidate (E) and the propofol groups (P). Anesthesia was induced and maintained by a remifentanil hydrochloride TCI combined with etomidate or propofol. The depth of anesthesia and other relevant indicators were recorded through intraoperative electroencephalogram monitoring using a Narcotrend monitor. RESULTS: No statistically significant differences were observed between the drug withdrawal times, eye opening requirements, or orientation recoveries of the two groups (P>0.05). The cortisol and aldosterone levels in group E were significantly lower than those in group P 24h post operation (P<0.05). No significant differences between the number of operations, hospitalization duration, mean arterial pressure, heart rate, and postoperative adverse reaction incidence of the two groups were observed at each time point (P>0.05). CONCLUSION: The application of a composite remifentanil hydrochloride combined with etomidate TCI is feasible for the early eschar excision in patients with severe burns.
